Ann: Full Year Statutory Accounts and Appendix 4E, page-2

Ladies and gentlemen - this is the most important part of the report. It is from the auditors.

Take not as it is a very serious thing that is directed to those who put their fingers in their ears and utter nah nah nah continually when any serious discussion on Biotron's finances are concerned. This may be a rude awakening for those people.

(e) Going concern
The financial statements have been prepared on a going concern basis which contemplates the realisation of
assets and settlement of liabilities in the ordinary course of business.
The Company has incurred a trading loss of $2,781,083 for the year ended 30 June 2022 and has accumulated
losses of $51,837,373 at 30 June 2022. The Company has cash on hand of $1,741,405 at 30 June 2022 and
used $3,994,573 of cash in operations for the year ended 30 June 2022 and received $1,558,525 in research
and development government incentives. As at 30 June 2022, the Company had net assets of $1,092,496.
These conditions give rise to a material uncertainty that may cast significant doubt upon the Company's ability
to continue as a going concern.
The ongoing operation of the Company is dependent on:
• the Company raising additional funding from shareholders or other parties; and/or
• the Company reducing expenditure in line with available funding.

Not a good sign either today - 9 trades for a total of $6 - three times more sellers than buyers.

BIT really does need to sort out its finances. The auditors strongly indicate that solving this issue is critical.